Krystal Biotech Inc and Jeune Aesthetics Inc PEARL-1 Extension Cohort Results and the KB301 Clinical Development Program - Corporate Call Transcript
Good morning, and thank you for joining us on Jeune Aesthetics, Inc. call to discuss data from our PEARL-1 durability results. My name is Meg Dodge, Head of Investor Relations and Communications at Krystal Biotech. I'd like to remind listeners that Jeune Aesthetics is a wholly owned subsidiary of Krystal Biotech.
Additionally, this presentation and the questions and answers may contain forward-looking statements, which are based on our current expectations and beliefs. For forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please see the panel entitled Forward Looking Statements in Krystal Biotech's filings with the SEC, including its most recent filings on Forms 10-K and 10-Q for a discussion of important risk factors that could cause actual events or results to differ materially from those in these forward-looking statements.
Today's call will be recorded and available on the Investors section of our website. At this time, I'd like
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
